EP3031465A4 - Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient - Google Patents

Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient Download PDF

Info

Publication number
EP3031465A4
EP3031465A4 EP14819974.8A EP14819974A EP3031465A4 EP 3031465 A4 EP3031465 A4 EP 3031465A4 EP 14819974 A EP14819974 A EP 14819974A EP 3031465 A4 EP3031465 A4 EP 3031465A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
active ingredient
bone tissue
leaf extract
tissue formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14819974.8A
Other languages
German (de)
French (fr)
Other versions
EP3031465A1 (en
EP3031465B1 (en
Inventor
Chul Yung Choi
Sang O Pan
Hee Jin Seol
Gyu Ok Lee
Wook Jin Jang
Hee Sook Kim
Jae Yong Kim
Hu Won Kang
Dong Wook Lee
Sun Oh Kim
Jae Gap Kim
Joon Yung Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yungjin Pharmaceutical Co Ltd
Jeonnam Bioindustry Foundation
Original Assignee
Yungjin Pharmaceutical Co Ltd
Jeonnam Bioindustry Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yungjin Pharmaceutical Co Ltd, Jeonnam Bioindustry Foundation filed Critical Yungjin Pharmaceutical Co Ltd
Priority to PL14819974T priority Critical patent/PL3031465T3/en
Publication of EP3031465A1 publication Critical patent/EP3031465A1/en
Publication of EP3031465A4 publication Critical patent/EP3031465A4/en
Application granted granted Critical
Publication of EP3031465B1 publication Critical patent/EP3031465B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP14819974.8A 2013-06-30 2014-04-29 Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient Active EP3031465B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL14819974T PL3031465T3 (en) 2013-06-30 2014-04-29 Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130076190A KR101532832B1 (en) 2013-06-30 2013-06-30 Composition for stimulating bone or bone tissue comprising extracts of leaves of stauntonia hexaphylla
PCT/KR2014/003742 WO2015002378A1 (en) 2013-06-30 2014-04-29 Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient

Publications (3)

Publication Number Publication Date
EP3031465A1 EP3031465A1 (en) 2016-06-15
EP3031465A4 true EP3031465A4 (en) 2017-03-01
EP3031465B1 EP3031465B1 (en) 2019-11-13

Family

ID=52143929

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14819974.8A Active EP3031465B1 (en) 2013-06-30 2014-04-29 Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient

Country Status (10)

Country Link
US (1) US10328110B2 (en)
EP (1) EP3031465B1 (en)
JP (1) JP6104462B2 (en)
KR (1) KR101532832B1 (en)
CN (2) CN105407903B (en)
AU (1) AU2014284932B2 (en)
CA (1) CA2911745C (en)
ES (1) ES2767351T3 (en)
PL (1) PL3031465T3 (en)
WO (1) WO2015002378A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102038108B1 (en) * 2016-12-29 2019-10-29 영진약품 주식회사 Novel caffeic acid compound from Stauntonia hexaphyll leaf extract and composition for anti-inflammatory, and improvement of bone tissue generation or cartilage tissue generation
KR102038107B1 (en) * 2016-12-29 2019-10-29 영진약품 주식회사 Novel flavonoid compound from Stauntonia hexaphyll leaf extract and composition for anti-inflammatory, and improvement of bone tissue generation or cartilage tissue generation
CN107259256B (en) * 2017-07-18 2020-12-29 福建农林大学 Functional beverage of radix fici simplicissimae and preparation method thereof
KR102126575B1 (en) * 2017-11-03 2020-06-24 영진약품 주식회사 Pharmaceutical composition for anti-inflammatory, and improvement of bone tissue generation or cartilage tissue generation comprising purified fraction materials from Stauntonia hexaphylla leaves or flavonoid compounds and caffeic acid compounds separated therefrom as active ingredients
KR102241369B1 (en) * 2020-02-25 2021-04-15 영진약품 주식회사 Pharmaceutical composition for anti-inflammatory, and improvement of bone tissue generation or cartilage tissue generation comprising purified fraction materials from Stauntonia hexaphylla leaves or flavonoid compounds and caffeic acid compounds separated therefrom as active ingredients
KR102625435B1 (en) * 2023-03-17 2024-01-18 (주)제이비 바이오 Fermented Stauntonia hexaphylla using a natural fermented enzyme complex and a composition for bone density improvement, bone growth promotion, height growth promotion or joint health promotion using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101221617B1 (en) * 2012-04-16 2013-01-14 재단법인 전라남도생물산업진흥재단 Anti-inflammatory agent containing stauntonia hexaphyllafruit leaf extract
KR20130020095A (en) * 2011-08-18 2013-02-27 재단법인 전라남도생물산업진흥재단 Hepatoprotective composition containing stauntonia hexaphylla extract
KR101243115B1 (en) * 2012-04-17 2013-03-12 재단법인 전라남도생물산업진흥재단 A fever reducer containing stauntonia hexaphyllafruit leaf extract
KR101317668B1 (en) * 2012-09-03 2013-10-15 재단법인 전라남도생물산업진흥재단 Pharmaceutical composition for treating and preventing arthritis comprising stauntonia hexaphylla leaf extract

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100497945B1 (en) * 2001-06-26 2005-06-29 한국 한의학 연구원 Extract of herb for promoting release of growth hormone
JP2011195532A (en) * 2010-03-23 2011-10-06 Shiseido Co Ltd Protein glycation inhibitor
JP2011201811A (en) * 2010-03-25 2011-10-13 Shiseido Co Ltd Tie2 activation agent, agent for maturing, normalizing or stabilizing blood vessel, agent for stabilizing lymphatic vessel, wrinkle-preventing and improving agent and dropsy-improving and preventing agent
JPWO2012133825A1 (en) * 2011-03-31 2014-07-28 株式会社 資生堂 Hot flash inhibitor
ES2752249T3 (en) * 2011-08-18 2020-04-03 Jeonnam Bioindustry Found Chemical composition comprising Stauntonia Hexaphylla extract
KR101167589B1 (en) 2011-08-18 2012-07-27 재단법인 전라남도생물산업진흥재단 Anti-inflammatory agent containing stauntonia hexaphylla fruit extract

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130020095A (en) * 2011-08-18 2013-02-27 재단법인 전라남도생물산업진흥재단 Hepatoprotective composition containing stauntonia hexaphylla extract
KR101221617B1 (en) * 2012-04-16 2013-01-14 재단법인 전라남도생물산업진흥재단 Anti-inflammatory agent containing stauntonia hexaphyllafruit leaf extract
KR101243115B1 (en) * 2012-04-17 2013-03-12 재단법인 전라남도생물산업진흥재단 A fever reducer containing stauntonia hexaphyllafruit leaf extract
KR101317668B1 (en) * 2012-09-03 2013-10-15 재단법인 전라남도생물산업진흥재단 Pharmaceutical composition for treating and preventing arthritis comprising stauntonia hexaphylla leaf extract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015002378A1 *

Also Published As

Publication number Publication date
EP3031465A1 (en) 2016-06-15
WO2015002378A1 (en) 2015-01-08
ES2767351T3 (en) 2020-06-17
CN105407903A (en) 2016-03-16
PL3031465T3 (en) 2020-05-18
US10328110B2 (en) 2019-06-25
CN105407903B (en) 2020-08-07
JP6104462B2 (en) 2017-03-29
US20160113979A1 (en) 2016-04-28
JP2016520059A (en) 2016-07-11
AU2014284932B2 (en) 2017-09-14
EP3031465B1 (en) 2019-11-13
CA2911745A1 (en) 2015-01-08
KR20150002398A (en) 2015-01-07
AU2014284932A1 (en) 2015-11-26
KR101532832B1 (en) 2015-06-30
CA2911745C (en) 2019-08-06
CN111494474A (en) 2020-08-07

Similar Documents

Publication Publication Date Title
EP3263135A4 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
HK1219432A1 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
EP3165227A4 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
EP2947084B8 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
IL237839A0 (en) Hydropyrrolopyrrole derivatives, their preparation and pharmaceutical compositions containing them
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
IL235414A (en) Pyrrolotriazinone derivatives, their preparation and pharmaceutical compositions containing them
EP3067059A4 (en) Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient
EP3031465A4 (en) Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient
EP3069720A4 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
EP3180993A4 (en) Composition for improving skin, containing pomegranate concentrate as active ingredient
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
HK1204563A1 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
IL246406A0 (en) Imidazopyrazinone derivatives, their preparation and pharmaceutical compositions containing them
IL246298A0 (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
EP3068436A4 (en) Topical pharmaceutical, cosmetic and disinfectant compositions comprising phosphatidylcholine
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
EP3158998A4 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EP2929786A4 (en) Composition comprising natural polyphenol compounds, and composition for oral administration comprising same
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
EP2799082A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
HK1204289A1 (en) Topical ophthalmological pharmaceutical composition containing cediranib
EP2910246A4 (en) Pharmaceutical composition for preventing or treating cancer, containing enoblock as active ingredient

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170126

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/16 20060101ALI20170120BHEP

Ipc: A61P 19/00 20060101ALI20170120BHEP

Ipc: A61K 36/71 20060101AFI20170120BHEP

Ipc: A61K 9/20 20060101ALI20170120BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEE, DONG WOOK

Inventor name: SEOL, HEE JIN

Inventor name: PARK, JOON YUNG

Inventor name: KIM, JAE YONG

Inventor name: KIM, HEE SOOK

Inventor name: PAN, SANG O

Inventor name: CHOI, CHUL YUNG

Inventor name: KANG, HU WON

Inventor name: LEE, GYU OK

Inventor name: KIM, JAE GAP

Inventor name: KIM, SUN OH

Inventor name: JANG, WOOK JIN

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KIM, SUN OH

Inventor name: KIM, HEE SOOK

Inventor name: PAN, SANG O

Inventor name: KIM, JAE YONG

Inventor name: KIM, JAE GAP

Inventor name: CHOI, CHUL YUNG

Inventor name: JANG, WOOK JIN

Inventor name: PARK, JOON YUNG

Inventor name: LEE, DONG WOOK

Inventor name: SEOL, HEE JIN

Inventor name: KANG, HU WON

Inventor name: LEE, GYU OK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190701

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1200981

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014056865

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191113

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200214

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200213

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200213

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200313

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200313

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2767351

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014056865

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1200981

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602014056865

Country of ref document: DE

Representative=s name: HL KEMPNER PATENTANWAELTE, SOLICITORS (ENGLAND, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602014056865

Country of ref document: DE

Representative=s name: HL KEMPNER PATENTANWALT, RECHTSANWALT, SOLICIT, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230321

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230323

Year of fee payment: 10

Ref country code: IT

Payment date: 20230321

Year of fee payment: 10

Ref country code: BE

Payment date: 20230321

Year of fee payment: 10

Ref country code: TR

Payment date: 20230331

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230530

Year of fee payment: 10

Ref country code: DE

Payment date: 20230320

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240320

Year of fee payment: 11